The standard of care for women's health was not designed for optimization. It was designed for disease management — and often, crisis intervention. Annual exams check for problems that have already developed. Hormone levels are tested only when symptoms become severe enough to warrant investigation. Thyroid panels are incomplete. Iron studies are overlooked. And the transition through perimenopause, which can last a decade and fundamentally reshape a woman's biology, is met with little more than a prescription for the pill or a recommendation to "wait it out."
This is not a failure of individual practitioners. It is a structural limitation of a system that was built around acute care, constrained by insurance billing codes, and historically under-researched when it comes to female-specific physiology. Women deserve better — and the science now exists to deliver it.
A standard hormonal assessment for women often consists of little more than a TSH test for thyroid function and, occasionally, an FSH level if menopause is suspected. This barely scratches the surface of the hormonal interplay that governs everything from energy and mood to body composition, bone density, cognitive function, and cardiovascular risk.
A comprehensive women's hormonal panel should include:
When a woman says she feels exhausted, foggy, and unlike herself — and her standard labs come back "normal" — the labs are not comprehensive enough. The problem is not imaginary. The testing is inadequate.
Perimenopause is not menopause. It is the transition — typically beginning in the late thirties or early forties — during which hormonal fluctuations become increasingly erratic before menstruation eventually ceases. This transition can last seven to ten years, and for many women, it is profoundly disruptive.
Symptoms of perimenopause include irregular cycles, sleep disruption, mood changes, weight gain (particularly around the midsection), decreased libido, brain fog, joint pain, increased anxiety, hot flashes, and changes in skin and hair. Many women experience these symptoms for years before receiving any clinical explanation — often being told their labs are "within normal range" because their doctor tested the wrong markers at the wrong time.
During perimenopause, hormone levels do not simply decline in a straight line. They fluctuate wildly — estrogen can spike to levels higher than reproductive prime before crashing to postmenopausal levels, sometimes within the same cycle. Progesterone, by contrast, tends to decline more steadily, creating an estrogen-dominant state that drives many of the most uncomfortable symptoms.
This volatility makes perimenopause difficult to diagnose with a single blood draw and even more difficult to manage with a one-size-fits-all approach. Effective management requires serial testing, symptom tracking, and individualized protocols that adapt as the hormonal landscape shifts.
For two decades following the 2002 Women's Health Initiative (WHI) study, hormone replacement therapy (HRT) was widely feared. The WHI reported increased risks of breast cancer and cardiovascular events in women taking oral conjugated equine estrogen plus synthetic progestin. The result was a mass abandonment of HRT that left an entire generation of women suffering through menopause without treatment.
Subsequent reanalysis of the WHI data — and two decades of additional research — has fundamentally revised the picture:
The current position of the North American Menopause Society, the Endocrine Society, and multiple international bodies is clear: for symptomatic women under 60 or within 10 years of menopause, the benefits of appropriately prescribed HRT outweigh the risks for most patients.
Hormone optimization is critical, but it is not the whole story. Women's health optimization also requires attention to:
Women lose bone mass at an accelerated rate during and after menopause due to estrogen decline. DEXA scanning should begin earlier than the standard recommendation of age 65 — particularly for women with risk factors like low body weight, family history, or early menopause. Resistance training, adequate calcium and vitamin D, and in some cases hormone therapy are the most effective strategies for preserving bone density.
Heart disease is the leading cause of death in women, yet cardiovascular risk assessment in women lags behind men's. Standard lipid panels miss important markers like Lp(a) and ApoB. Inflammatory markers like hs-CRP are particularly predictive in women. And the protective cardiovascular effect of estrogen means that the post-menopausal transition is a critical window for risk assessment and intervention.
Iron deficiency is remarkably common in premenopausal women due to menstrual blood loss, yet it is rarely tested unless anemia is already present. Ferritin levels below 30 ng/mL — well within "normal" range — are associated with fatigue, hair loss, poor exercise tolerance, and impaired cognitive function. Optimal ferritin for women who menstruate is typically 50 to 100 ng/mL.
Women face a steeper sarcopenia curve than men after menopause, driven by declining estrogen and testosterone. Resistance training — heavy enough to challenge the musculoskeletal system — is not optional for women over 40. It is arguably the single most important exercise modality for long-term health, independence, and metabolic function.
At ALYZE, women's health optimization begins with comprehensive testing that goes far beyond the standard of care — full hormonal panels, complete thyroid assessment, inflammatory markers, metabolic panels, body composition via DEXA, and cardiovascular risk profiling. The results are interpreted not in isolation, but in the context of your symptoms, your goals, your life stage, and your complete health picture.
Because the goal is not to treat a disease. The goal is to ensure that every system in your body is functioning at its best — and that you have the data, the team, and the environment to make that happen.
Bountiful, Utah · alyze.health
